GlassScriptPhysician profile
Muhammad Hasham Sarwar
NPI 1194250696
$5,155.97
in general payments reported to CMS, 2019-2025
19 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $347 · 2022: $711 · 2023: $581 · 2024: $3,148 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Food and Beverage: $1,054 · Travel and Lodging: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Food and Beverage | $1,054.39 |
| Travel and Lodging | $543.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,655.56 | 2024 | |
| Olympus Corporation of The Americas | $794.32 | 2022-2023 | Single Use Suction Valve (Sterile) |
| Astrazeneca Pharmaceuticals LP | $372.75 | 2021-2025 | Airsupra, Fasenra, Andexxa |
| Glaxosmithkline, LLC. | $231.37 | 2022-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Abiomed | $200.52 | 2024-2025 | Impella |
| Olympus America INC. | $183.02 | 2021-2022 | |
| Amgen INC. | $138.75 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.42 | 2021-2025 | Ofev |
| Merck Sharp & Dohme LLC | $84.38 | 2023-2025 | Winrevair, Keytruda, Dificid |
| Regeneron Healthcare Solutions, INC. | $72.62 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $63.97 | 2023-2024 | Yupelri |
| Baxter Healthcare | $62.79 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $57.99 | 2021 | |
| Shionogi INC | $36.55 | 2024-2025 | Fetroja |
| Ani Pharmaceuticals, INC. | $22.29 | 2024 | Purified Cortrophin Gel |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.08 | 2024 | |
| Verona Pharma, INC. | $16.27 | 2025 | Ohtuvayre |
| Electromed, INC. | $15.99 | 2025 | Smartvest |
| Janssen Pharmaceuticals, INC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Hasham Sarwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.